Key Highlights
•
A new review links dysfunction in the brain’s wake-promoting systems (like norepinephrine and orexin) to the early stages of Alzheimer’s disease, even before memory problems appear. This dysfunction disrupts sleep and impairs the brain’s natural cleaning system, potentially creating a vicious cycle that accelerates the buildup of toxic proteins.
Source →
•
Researchers propose that a brain scan complication seen with new Alzheimer’s drugs, known as ARIA, stems from the drugs clearing amyloid protein in a way that can overwhelm and inflame fragile blood vessels in the brain. Understanding this risk is critical for safely monitoring patients on these promising new therapies.
Source →
•
A study found that in patients without Alzheimer’s amyloid plaques, damage to the brain’s white matter (seen on scans as hyperintensities) is linked to reduced energy use in specific brain regions and worse cognitive performance. This highlights that factors other than amyloid, like blood vessel health, are major contributors to memory loss.
Source →
•
A European study of patients with a lung-scarring disease linked to a specific antibody (ANCA) found that nearly half died over a 4-year period, with older age and worse lung function being key predictors. The research suggests that certain immunosuppressant drugs, like rituximab, may help preserve lung function in these patients.
Source →
•
A study on Cushing syndrome, a disorder of high cortisol, points out that the condition is likely underdiagnosed because its symptoms are common and current tests often miss the problem, especially in mild cases. The review argues that tracking a patient’s natural 24-hour cortisol rhythm, rather than single measurements, could significantly improve diagnosis and treatment monitoring.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
